Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06264180

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]

Sponsor: Replimune Inc.

Conditions Advanced Melanoma

Interventions Nivolumab Nivolumab + Relatlimab Pembrolizumab Single-agent chemotherapy Vusolimogene Oderparepvec

Updated 15 times since 2024 Last updated: Mar 12, 2026 Started: Jul 11, 2024 Primary completion: Jan 1, 2029 Completion: Aug 31, 2034

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Advanced Melanoma and is currently actively recruiting participants. Replimune Inc. leads this study, which shows 15 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Oct 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3

▶ Show 10 earlier versions

Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE3
May 2025 — Jul 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Mar 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Replimune Inc.

Data source: Replimune Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Barcelona, Spain , Berlin, Germany , Buffalo, United States , Burlington, United States , Camden, United States , Chapel Hill, United States , Chicago, United States , Columbus, United States and 56 more locations